A systematic review of the safety and efficacy of convalescent plasma or immunoglobulin treatment for people with severe respiratory viral infections due to coronaviruses or influenza.
Journal article
Kimber C. et al, (2022), Transfus Med
Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma
Journal article
Estcourt LJ. et al, (2022), Annals of Internal Medicine
UK audit of the management of major bleeding and time taken to deliver blood products
Journal article
Green L. et al, (2022), British Journal of Anaesthesia
Reply to comment on: Massive transfusion experience, current practice and decision support: A survey of Australian and New Zealand Anaesthetists.
Journal article
Sanderson BJ. et al, (2022), Anaesth Intensive Care, 50, 337 - 338
Assessing efficacy and safety of replacement fluids in therapeutic plasma exchange: A systematic scoping review of outcome measures used
Journal article
Kohli R. et al, (2022), Journal of Clinical Apheresis
Insights from developing and evaluating the NHS blood choices transfusion app to support junior and middle‐grade doctor decision making against guidelines
Journal article
Dhesi AS. et al, (2022), Transfusion Medicine
Convalescent plasma donors show enhanced cross-reactive neutralising antibody response to antigenic variants of SARS-CoV-2 following immunisation.
Journal article
Harvala H. et al, (2022), Transfusion
Convalescent Plasma for Covid-19 - Making Sense of the Inconsistencies.
Journal article
Estcourt L. and Callum J., (2022), N Engl J Med, 386, 1753 - 1754
Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR.
Journal article
Ratcliff J. et al, (2022), J Clin Microbiol
Determinants of passive antibody effectiveness in SARS-CoV-2 infection
Preprint
Stadler E. et al, (2022)
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Journal article
REMAP-CAP Writing Committee for the REMAP-CAP Investigators None. et al, (2022), JAMA
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676
Passive immune therapies: another tool against COVID-19.
Journal article
Estcourt LJ., (2021), Hematology Am Soc Hematol Educ Program, 2021, 628 - 641
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
Journal article
Axfors C. et al, (2021), BMC Infectious Diseases, 21
Highly-Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe Polymerase Chain Reaction
Preprint
Ratcliff J. et al, (2021)
The difference in potential harms between whole blood and component blood transfusion in major bleeding: a rapid systematic review and meta-analysis of RCTs
Journal article
Geneen LJ. et al, (2021), Transfusion Medicine Reviews
Hyperimmune immunoglobulin for people with COVID-19
Journal article
Kimber C. et al, (2021), Cochrane Database of Systematic Reviews, 2021
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Journal article
Writing Committee for the REMAP-CAP Investigators None. et al, (2021), JAMA
Living systematic reviews in a context of rapidly emerging diseases: challenges and lessons learned
Conference paper
Iannizzi C. et al, (2021), EUROPEAN JOURNAL OF PUBLIC HEALTH, 31, 182 - 182
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Journal article
Ernst M. et al, (2021), Cochrane Database Syst Rev, 9